Recap: Synlogic Q1 Earnings

Shares of Synlogic SYBX rose 2.7% in pre-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share were up 9.80% year over year to ($0.46), which missed the estimate of ($0.43).

Revenue of $100,000 less by 70.41% year over year, which missed the estimate of $450,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

Synlogic hasn't issued any revenue guidance for the time being.

Conference Call Details

Date: May 08, 2020

Webcast URL: https://edge.media-server.com/mmc/p/o38dmqqm

Recent Stock Performance

52-week high: $10.01

Company's 52-week low was at $1.35

Price action over last quarter: Up 44.65%

Company Profile

Synlogic Inc is a biopharmaceutical company focused on advancing the drug discovery and development platform for Synthetic Biotic medicines, which are designed using synthetic biology to genetically reprogram beneficial microbes to treat metabolic and inflammatory diseases and cancer.

Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNews
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...